Drugs from Eli Lilly and Boehringer Ingelheim grabbed the spotlight at the EASL congress on liver diseases, both showing promising results in metabolic dysfunction-associated steatohepatitis (MASH).
Boehringer Ingelheim’s weight-loss drug candidate survodutide could also be effective for liver disease metabolic dysfunction-associated steatohepatitis (MASH), if the results of a mid-stage trial are ...
The beverage industry is buzzing, and 2025 looks like a great year to jump in. Whether you’re into craft brews, fine wines, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback